Stifel Nicolaus Has Lowered Expectations for X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price

X4 Pharmaceuticals (NASDAQ:XFOR) had its price objective decreased by investment analysts at Stifel Nicolaus from $5.00 to $4.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

X4 Pharmaceuticals Stock Performance

Shares of XFOR stock opened at $0.40 on Thursday. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. The company has a market cap of $67.99 million, a PE ratio of -4.42 and a beta of 0.39. The company’s fifty day simple moving average is $0.59 and its 200-day simple moving average is $0.75. X4 Pharmaceuticals has a 52 week low of $0.26 and a 52 week high of $1.60.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings data on Wednesday, August 14th. The company reported $0.01 EPS for the quarter. The firm had revenue of $3.43 million during the quarter. As a group, equities research analysts anticipate that X4 Pharmaceuticals will post -0.65 EPS for the current year.

Insider Activity at X4 Pharmaceuticals

In other X4 Pharmaceuticals news, COO Mary Dibiase sold 67,695 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $0.57, for a total value of $38,586.15. Following the sale, the chief operating officer now directly owns 452,060 shares of the company’s stock, valued at $257,674.20. This trade represents a 13.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the sale, the chief executive officer now owns 1,057,713 shares in the company, valued at approximately $581,742.15. This represents a 18.46 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 580,800 shares of company stock valued at $321,447. Insiders own 1.62% of the company’s stock.

Institutional Investors Weigh In On X4 Pharmaceuticals

Large investors have recently made changes to their positions in the company. GSA Capital Partners LLP bought a new position in X4 Pharmaceuticals in the 3rd quarter worth approximately $340,000. K2 Principal Fund L.P. acquired a new position in X4 Pharmaceuticals during the 2nd quarter worth $284,000. AQR Capital Management LLC grew its stake in shares of X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares in the last quarter. State Street Corp grew its stake in shares of X4 Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,952,895 shares of the company’s stock worth $1,976,000 after purchasing an additional 189,105 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of X4 Pharmaceuticals by 196.0% during the third quarter. Barclays PLC now owns 277,682 shares of the company’s stock valued at $185,000 after purchasing an additional 183,861 shares in the last quarter. Institutional investors and hedge funds own 72.03% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.